Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:04:52.443Z.
Calculation as of: 2026-10-06T20:04:52.443Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$225.24M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$231.77M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$235.08M
Price/OCF Ratio
19.84
TTM Avg
15.29
3Y Avg
13.49
5Y Avg
14.36
Market Cap
$235.66M
Price/OCF Ratio
5.67
TTM Avg
7.79
3Y Avg
7.79
5Y Avg
7.79
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vogenx Inc. (VOGX) | $227.91M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | N/A | 62.49 | 62.49 | 62.49 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A | N/A | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 19.84 | 15.29 | 13.49 | 14.36 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | 5.67 | 7.79 | 7.79 | 7.79 |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | N/A | 6.47 | 15.02 | 16.17 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
